Germany's Evotec Gets Takeover Interest From Halozyme [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Most Read from Bloomberg Under Trump, Prepare for New US Transportation Priorities Zimbabwe City of 700,000 at Risk of Running Dry by Year-End Saudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency Sace NYC Congestion Pricing Plan With $9 Toll to Start in January The Urban-Rural Divide Over Highway Expansion and Emissions Halozyme has recently expressed interest in acquiring Evotec at about €11 per share, the people said, asking not to be identified because the information is private. That would represent a roughly 27% premium to Evotec's closing price on Thursday and would value the German drug developer at nearly €2 billion ($2.1 billion). Evotec's American depositary receipts rose as much as 19% Thursday and were up 12% at 2:59 p.m. in New York, giving the company a market value of $1.8 billion. San Diego, California-based Halozyme's shares, after falling as much as 7.3%, were down 5.3%, giving it a market value of about $7 billion. Consideration
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.MarketBeat
- How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 10/31/24 - Beat
HALO
Sec Filings
- 12/3/24 - Form 4
- 12/3/24 - Form 4
- 11/12/24 - Form SC
- HALO's page on the SEC website